3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the health services industry lower today.
By TheStreet Wire ,

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 29 points (0.2%) at 18,546 as of Friday, July 22, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,820 issues advancing vs. 1,037 declining with 178 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is up 0.3%. A company within the industry that fell today was

Valeant Pharmaceuticals International

(

VRX

), up 4.1%. Top gainers within the industry include

Biogen

(

BIIB

), up 2.7%,

Novo Nordisk A/S

(

NVO

), up 0.9%,

GlaxoSmithKline

(

GSK

), up 0.6% and

Celgene

(

CELG

), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Abaxis

(

ABAX

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Abaxis is down $7.66 (-14.0%) to $47.09 on heavy volume. Thus far, 570,416 shares of Abaxis exchanged hands as compared to its average daily volume of 158,100 shares. The stock has ranged in price between $46.81-$49.50 after having opened the day at $49.50 as compared to the previous trading day's close of $54.75.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. Abaxis has a market cap of $1.2 billion and is part of the health care sector. Shares are down 1.7% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst that rates Abaxis a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Abaxis

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and good cash flow from operations. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Abaxis Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Incyte

(

INCY

) is down $0.93 (-1.1%) to $86.86 on light volume. Thus far, 317,494 shares of Incyte exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $86.47-$88.99 after having opened the day at $88.47 as compared to the previous trading day's close of $87.79.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. Incyte has a market cap of $16.3 billion and is part of the health care sector. Shares are down 19.1% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Incyte a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Incyte

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, poor profit margins and generally higher debt management risk. Get the full

Incyte Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Alexion Pharmaceuticals

(

ALXN

) is down $0.73 (-0.6%) to $126.57 on light volume. Thus far, 698,603 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $125.34-$127.98 after having opened the day at $127.74 as compared to the previous trading day's close of $127.30.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $28.4 billion and is part of the health care sector. Shares are down 33.3% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Alexion Pharmaceuticals

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and feeble growth in the company's earnings per share. Get the full

Alexion Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...